The genetics and epigenetics of autoimmune diseases

Journal of Autoimmunity

Volumn 33, Issue 1, 2009, Pages 3-11

  Hewagama, Anura ^a   Richardson, Bruce ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Epigenetics; Genetics; Lupus; Multiple Sclerosis; Rheumatoid Arthritis

Indexed keywords

AZACITIDINE; DNA; HISTONE; HYDRALAZINE; PROCAINAMIDE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DNA METHYLATION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENE NUMBER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS LIKE SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; X CHROMOSOME;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHROMOSOMES, HUMAN, X; ENVIRONMENTAL EXPOSURE; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SELF TOLERANCE; X CHROMOSOME INACTIVATION;

EID: 67349236051     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.03.007     Document Type: Review

References (110)

1. Wandstrat A., and Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2 (2001) 802-809
2. Alarcon-Riquelme M.E. Recent advances in the genetics of autoimmune diseases. Ann N Y Acad Sci 1110 (2007) 1-9
3. Strickland F.M., and Richardson B.C. Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 41 (2008) 278-286
4. Ahmed S.A., Hissong B.D., Verthelyi D., Donner K., Becker K., and Karpuzoglu-Sahin E. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect 107 Suppl. 5 (1999) 681-686
5. Rider V., Foster R.T., Evans M., Suenaga R., and Abdou N.I. Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus. Clin Immunol Immunopathol 89 (1998) 171-180
6. Sinha S., Kaler L.J., Proctor T.M., Teuscher C., Vandenbark A.A., and Offner H. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol 180 (2008) 2679-2685
7. Yung R., Chang S., Hemati N., Johnson K., and Richardson B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 40 (1997) 1436-1443
8. Herrera B.M., Cader M.Z., Dyment D.A., Bell J.T., Deluca G.C., Willer C.J., et al. Multiple sclerosis susceptibility and the X chromosome. Mult Scler 13 (2007) 856-864
9. Yin X., Latif R., Tomer Y., and Davies T.F. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 1110 (2007) 193-200
10. Bird A.P. Gene number, noise reduction and biological complexity. Trends Genet 11 (1995) 94-100
11. Berger S.L. The complex language of chromatin regulation during transcription. Nature 447 (2007) 407-412
12. Dashwood R.H., and Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17 (2007) 363-369
13. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 3 (2002) 662-673
14. Zhang Y., and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15 (2001) 2343-2360
15. Jarvinen P., and Aho K. Twin studies in rheumatic diseases. Semin Arthritis Rheum 24 (1994) 19-28
16. Sestak A.L., Shaver T.S., Moser K.L., Neas B.R., and Harley J.B. Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. J Rheumatol 26 (1999) 1495-1499
17. Sestak A., and O'Neil K.M. Familial lupus and antiphospholipid syndrome. Lupus 16 (2007) 556-563
18. Sestak A.L., Nath S.K., Sawalha A.H., and Harley J.B. Current status of lupus genetics. Arthritis Res Ther 9 (2007) 210
19. Jonsen A., Bengtsson A.A., Sturfelt G., and Truedsson L. Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res Ther 6 (2004) R557-R562
20. Karassa F.B., Trikalinos T.A., and Ioannidis J.P. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother 58 (2004) 286-291
21. Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S., Carlton V.E., et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75 (2004) 504-507
22. Suarez A., Lopez P., Mozo L., and Gutierrez C. Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 1605-1610
23. Rosado S., Rua-Figueroa I., Vargas J.A., Garcia-Laorden M.I., Losada-Fernandez I., Martin-Donaire T., et al. Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. Int J Immunogenet 35 (2008) 235-242
24. Tarassi K., Carthy D., Papasteriades C., Boki K., Nikolopoulou N., Carcassi C., et al. HLA-TNF haplotype heterogeneity in Greek SLE patients. Clin Exp Rheumatol 16 (1998) 66-68
25. Sullivan K.E., Suriano A., Dietzmann K., Lin J., Goldman D., and Petri M.A. The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. Clin Immunol 123 (2007) 74-81
26. Kim H.Y., Lee S.H., Yang H.I., Park S.H., Cho C.S., Kim T.G., et al. TNFB gene polymorphism in patients with systemic lupus erythematosus in Korean. Korean J Intern Med 10 (1995) 130-136
27. Sullivan K.E., Jawad A.F., Piliero L.M., Kim N., Luan X., Goldman D., et al. Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology (Oxford) 42 (2003) 446-452
28. Sullivan K.E., Petri M.A., Schmeckpeper B.J., McLean R.H., and Winkelstein J.A. Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. J Rheumatol 21 (1994) 1128-1133
29. Sullivan K.E., Kim N.A., Goldman D., and Petri M.A. C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus. J Rheumatol 26 (1999) 2144-2147
30. Miyagawa H., Yamai M., Sakaguchi D., Kiyohara C., Tsukamoto H., Kimoto Y., et al. Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology (Oxford) 47 (2008) 158-164
31. Speirs C., Fielder A.H., Chapel H., Davey N.J., and Batchelor J.R. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1 (1989) 922-924
32. Castano-Rodriguez N., Diaz-Gallo L.M., Pineda-Tamayo R., Rojas-Villarraga A., and Anaya J.M. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev 7 (2008) 322-330
33. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32 (2002) 666-669
34. Graham D.S., Wong A.K., McHugh N.J., Whittaker J.C., and Vyse T.J. Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study. Hum Mol Genet 15 (2006) 3195-3205
35. Parks C.G., Hudson L.L., Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., et al. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus 13 (2004) 784-791
36. Barreto M., Santos E., Ferreira R., Fesel C., Fontes M.F., Pereira C., et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12 (2004) 620-626
37. Taylor K.E., Remmers E.F., Lee A.T., Ortmann W.A., Plenge R.M., Tian C., et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 4 (2008) e1000084
38. Sigurdsson S., Nordmark G., Garnier S., Grundberg E., Kwan T., Nilsson O., et al. A common STAT4 risk haplotype for Systemic Lupus Erythematosus is over-expressed, correlates with anti-dsDNA production and shows additive effects with two IRF5 risk alleles. Hum Mol Genet (2008)
39. Kobayashi S., Ikari K., Kaneko H., Kochi Y., Yamamoto K., Shimane K., et al. Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum 58 (2008) 1940-1946
40. Deapen D., Escalante A., Weinrib L., Horwitz D., Bachman B., Roy-Burman P., et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35 (1992) 311-318
41. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol 17 (1986) 456-470
42. Rolink A.G., and Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 158 (1983) 546-558
43. Quddus J., Johnson K.J., Gavalchin J., Amento E.P., Chrisp C.E., Yung R.L., et al. Treating activated CD4 + T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92 (1993) 38-53
44. Yung R.L., Quddus J., Chrisp C.E., Johnson K.J., and Richardson B.C. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154 (1995) 3025-3035
45. Yung R.L., and Richardson B.C. Drug-induced lupus. Rheum Dis Clin North Am 20 (1994) 61-86
46. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140 (1988) 2197-2200
47. Lee B.H., Yegnasubramanian S., Lin X., and Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 280 (2005) 40749-40756
48. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., and Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 18 (1991) 530-534
49. Gorelik G., Fang J.Y., Wu A., Sawalha A.H., and Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 179 (2007) 5553-5563
50. Deng C., Kaplan M.J., Yang J., Ray D., Zhang Z., McCune W.J., et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 44 (2001) 397-407
51. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., and Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33 (1990) 1665-1673
52. Sawalha A.H., Jeffries M., Webb R., Lu Q., Gorelik G., Ray D., et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 9 (2008) 368-378
53. Alcolado J.C., Laji K., and Gill-Randall R. Maternal transmission of diabetes. Diabet Med 19 (2002) 89-98
54. Irvine D.J., Purbhoo M.A., Krogsgaard M., and Davis M.M. Direct observation of ligand recognition by T cells. Nature 419 (2002) 845-849
55. Yung R., Powers D., Johnson K., Amento E., Carr D., Laing T., et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 97 (1996) 2866-2871
56. Lu Q., Kaplan M., Ray D., Ray D., Zacharek S., Gutsch D., et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 1282-1291
57. Lu Q., Wu A., and Richardson B.C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174 (2005) 6212-6219
58. Kaplan M.J., Lu Q., Wu A., Attwood J., and Richardson B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol 172 (2004) 3652-3661
59. Oelke K., Lu Q., Richardson D., Wu A., Deng C., Hanash S., et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 50 (2004) 1850-1860
60. Koshy M., Berger D., and Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98 (1996) 826-837
61. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., and Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 179 (2007) 6352-6358
62. Crow M.K., and Kirou K.A. Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr Opin Rheumatol 13 (2001) 361-369
63. Batchelor J.R., Welsh K.I., Tinoco R.M., Dollery C.T., Hughes G.R., Bernstein R., et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1 (1980) 1107-1109
64. Alarcon-Segovia D., Alarcon-Riquelme M.E., Cardiel M.H., Caeiro F., Massardo L., Villa A.R., et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 52 (2005) 1138-1147
65. Wordsworth P., and Bell J. Polygenic susceptibility in rheumatoid arthritis. Ann Rheum Dis 50 (1991) 343-346
66. Orozco G., Rueda B., and Martin J. Genetic basis of rheumatoid arthritis. Biomed Pharmacother 60 (2006) 656-662
67. Orozco G., Pascual-Salcedo D., Lopez-Nevot M.A., Cobo T., Cabezon A., Martin-Mola E., et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology (Oxford) 47 (2008) 138-141
68. Zhernakova A., Eerligh P., Barrera P., Wesoly J.Z., Huizinga T.W., Roep B.O., et al. CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum Genet 118 (2005) 58-66
69. Firestein G. Rheumatoid synovitis and pannus, p. 876-879. In: S A., Hochberg M., Smolen J., Weinblatt M., and Weisman M. (Eds). Rheumatology (2003), Mosby, New York
70. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
71. Schwab J., and Illges H. Silencing of CD21 expression in synovial lymphocytes is independent of methylation of the CD21 promoter CpG island. Rheumatol Int 20 (2001) 133-137
72. Costenbader K.H., Chang S.C., De Vivo I., Plenge R., and Karlson E.W. Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res Ther 10 (2008) R52
73. Oksenberg J.R., Baranzini S.E., Sawcer S., and Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 9 (2008) 516-526
74. Ramagopalan S.V., Deluca G.C., Degenhardt A., and Ebers G.C. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol (2008)
75. Alonso A., and Hernan M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71 (2008) 129-135
76. Kragt J.J., Van Amerongen B.M., Killestein J., Dijkstra C.D., Uitdehaag B.M., Polman C.H., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler (2008)
77. Moscarello M.A., Mastronardi F.G., and Wood D.D. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 32 (2007) 251-256
78. Pitzalis M., Zavattari P., Murru R., Deidda E., Zoledziewska M., Murru D., et al. Genetic loci linked to type 1 diabetes and multiple sclerosis families in Sardinia. BMC Med Genet 9 (2008) 3
79. Ounissi-Benkalha H., and Polychronakos C. The molecular genetics of type 1 diabetes: new genes and emerging mechanisms. Trends Mol Med 14 (2008) 268-275
80. Knight J.C. Regulatory polymorphisms underlying complex disease traits. J Mol Med 83 (2005) 97-109
81. Peng H., and Hagopian W. Environmental factors in the development of Type 1 diabetes. Rev Endocr Metab Disord 7 (2006) 149-162
82. Robles D.T., and Eisenbarth G.S. Type 1A diabetes induced by infection and immunization. J Autoimmun 16 (2001) 355-362
83. Poirier L.A. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr 132 (2002) 2336S-2339S
84. Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., Moser K.L., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40 (2008) 204-210
85. Sullivan K.E. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 26 (2000) 229-256 v-vi
86. Karassa F.B., Bijl M., Davies K.A., Kallenberg C.G., Khamashta M.A., Manger K., et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 48 (2003) 1930-1938
87. Karassa F.B., Trikalinos T.A., and Ioannidis J.P. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 46 (2002) 1563-1571
88. Karassa F.B., Trikalinos T.A., and Ioannidis J.P. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 63 (2003) 1475-1482
89. D. A S., Giordano M., Mellai M., Lanceni M., Barizzone N., Marchini M., et al. Association tests with systemic lupus erythematosus (SLE) of IL10 markers indicate a direct involvement of a CA repeat in the 5' regulatory region. Genes Immun 3 (2002) 454-463
90. Alarcon-Riquelme M.E., Lindqvist A.K., Jonasson I., Johanneson B., Sandino S., Alcocer-Varela J., et al. Genetic analysis of the contribution of IL10 to systemic lupus erythematosus. J Rheumatol 26 (1999) 2148-2152
91. Torres B., Aguilar F., Franco E., Sanchez E., Sanchez-Roman J., Jimenez Alonso J., et al. Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis Rheum 50 (2004) 2211-2215
92. Aguilar F., Torres B., Sanchez-Roman J., Nunez-Roldan A., and Gonzalez-Escribano M.F. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 64 (2003) 936-940
93. Kristiansen O.P., Larsen Z.M., and Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity?. Genes Immun 1 (2000) 170-184
94. Prokunina L., Gunnarsson I., Sturfelt G., Truedsson L., Seligman V.A., Olson J.L., et al. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50 (2004) 327-328
95. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50 (2004) 1770-1773
96. Sawalha A.H., Kaufman K.M., Kelly J.A., Adler A.J., Aberle T., Kilpatrick J., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67 (2008) 458-461
97. Mascart-Lemone F., Hauptmann G., Goetz J., Duchateau J., Delespesse G., Vray B., et al. Genetic deficiency of C4 presenting with recurrent infections and a SLE-like disease. Genetic and immunologic studies. Am J Med 75 (1983) 295-304
98. Sullivan K.E., Wooten C., Schmeckpeper B.J., Goldman D., and Petri M.A. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 40 (1997) 2207-2211
99. Takeuchi F., Nakano K., Nabeta H., Hong G.H., Kawasugi K., Mori M., et al. Genetic contribution of the tumour necrosis factor (TNF) B + 252*2/2 genotype, but not the TNFa,b microsatellite alleles, to systemic lupus erythematosus in Japanese patients. Int J Immunogenet 32 (2005) 173-178
100. Parks C.G., Pandey J.P., Dooley M.A., Treadwell E.L., St Clair E.W., Gilkeson G.S., et al. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol 65 (2004) 622-631
101. Graham C., Manku D.S.H., Wagner S., Reid J., and Timms K. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16 (2007) 579-591
102. Ferreiro-Neira I., Calaza M., Alonso-Perez E., Marchini M., Scorza R., Sebastiani G.D., et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 8 (2007) 429-438
103. Nakashima H., Matsuno S., Akahoshi M., Miyake K., Inoue Y., Tanaka Y., et al. Association between IFNA genotype and the risk of systemic lupus erythematosus. Clin Rheumatol 24 (2005) 38-40
104. Lee Y.H., Witte T., Momot T., Schmidt R.E., Kaufman K.M., Harley J.B., et al. The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52 (2005) 3966-3974
105. Tangwattanachuleeporn M., Sodsai P., Avihingsanon Y., Wongpiyabovorn J., Wongchinsri J., and Hirankarn N. Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE. Clin Rheumatol 26 (2007) 1921-1924
106. Sullivan K.E., Wooten C., Goldman D., and Petri M. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 39 (1996) 2046-2051
107. Sawalha A.H., Webb R., Han S., Kelly J.A., Kaufman K.M., Kimberly R.P., et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 3 (2008) e1727
108. Rooryck C., Barnetche T., Richez C., Laleye A., Arveiler B., and Schaeverbeke T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 26 (2008) 340-342
109. Orozco G., Sanchez E., Gonzalez-Gay M.A., Lopez-Nevot M.A., Torres B., Pascual-Salcedo D., et al. SLC22A4, RUNX1, and SUMO4 polymorphisms are not associated with rheumatoid arthritis: a case-control study in a Spanish population. J Rheumatol 33 (2006) 1235-1239
110. de Vries N., Tijssen H., Jarvinen P., Aho K., and van de Putte L.B. HLA-DRB1 in eight Finnish monozygotic twin pairs concordant for rheumatoid arthritis. Tissue Antigens 49 (1997) 277-279